Mamoun Alhajjoumaa
Medical · Elmhurst, NYNPI 1285876466
Payments from drug & device makers
Across 395 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Bayer$2K
- AstraZeneca$784
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$589
- GSK$567
- Pfizer$350
- plus $3K from 28 others
What the payments were for
- Food & beverage$10,106100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 103 | $2,978 |
| Bayer | 46 | $1,751 |
| AstraZeneca | 34 | $784 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $589 |
| GSK | 25 | $567 |
| Pfizer | 19 | $350 |
| Novo Nordisk | 16 | $350 |
| Lilly USA, LLC | 13 | $300 |
| Daiichi Sankyo Inc. | 9 | $234 |
| Axsome Therapeutics, Inc. | 8 | $216 |
| Amgen(2 entities) | 6 | $215 |
| Amarin Pharma, Inc. | 10 | $214 |
| Ironwood Pharmaceuticals, Inc | 9 | $204 |
| Exact Sciences | 8 | $202 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $174 |
| Boehringer Ingelheim | 6 | $146 |
| Idorsia Pharmaceuticals US Inc | 6 | $125 |
| Sumitomo Pharma America, Inc. | 1 | $85 |
| Nevro Corp. | 2 | $64 |
| Ardelyx, Inc. | 3 | $62 |
| Novartis | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Redhill Biopharma Inc. | 2 | $49 |
| Astellas Pharma US Inc | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Merck | 2 | $31 |
| Vistapharm, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,106 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 599 | $274,739 |
| JardianceEmpagliflozin | 202 | $181,928 |
| KerendiaFinerenone | 156 | $134,708 |
| JanumetSitagliptin Phos/Metformin Hcl | 140 | $132,837 |
| FarxigaDapagliflozin Propanediol | 149 | $113,660 |
| VraylarCariprazine Hcl | 44 | $85,359 |
| LinzessLinaclotide | 137 | $85,206 |
| JanuviaSitagliptin Phosphate | 99 | $82,855 |
| OzempicSemaglutide | 67 | $72,744 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 54 | $69,411 |
| EliquisApixaban | 92 | $61,164 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $48,044 |
| NamzaricMemantine Hcl/Donepezil Hcl | 45 | $44,451 |
| UbrelvyUbrogepant | 27 | $36,656 |
| ProliaDenosumab | 18 | $29,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess, Namzaric, Ubrelvy, Creon | $2,978 | $302,847292 claims |
| MerckJanumet, Januvia, Janumet Xr | $31 | $285,103293 claims |
| Boehringer IngelheimJardiance, Jentadueto, Tradjenta | $146 | $227,508256 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $784 | $142,414202 claims |
| BayerKerendia | $1,751 | $134,708156 claims |
| Novo NordiskOzempic | $350 | $72,74467 claims |
| PfizerEliquis | $350 | $61,16492 claims |
| GSKTrelegy Ellipta, Arexvy | $567 | $52,54887 claims |
| AmgenProlia | $215 | $29,90918 claims |
| Lilly USA, LLCTrulicity | $300 | $22,57116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Elmhurst
- Maria NunezElmhurst$25K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.